Therna is advancing programmable RNA medicines across rare genetic disorders, immunological disorders, and cardiovascular disease, alongside single-patient programs for ultra-rare conditions.
Therapeutic Pipeline
Single-Patient Programs
Therna is selectively pursuing single-patient programs for ultra-rare conditions where conventional clinical development is not feasible. These efforts apply the RNA-Logix™ capabilities while generating biological insights that strengthen model performance across the broader pipeline.
